The incidence of vasculitides in Israel from 2007 to 2021 and during the COVID-19 pandemic.

Autor:	Zeller L; Rheumatology Disease Unit, Soroka University Medical Center, Beer Sheva, Israel.; Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheva, Israel., Ben David R; Rheumatology Disease Unit, Soroka University Medical Center, Beer Sheva, Israel.; Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheva, Israel., Novack L; Clinical Research Center, Soroka University Medical Center, Beer Sheva, Israel.; Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheva, Israel., Abuhasira R; Rheumatology Disease Unit, Soroka University Medical Center, Beer Sheva, Israel.; Clinical Research Center, Soroka University Medical Center, Beer Sheva, Israel.; Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheva, Israel., Abu-Shakra M; Rheumatology Disease Unit, Soroka University Medical Center, Beer Sheva, Israel.; Clinical Research Center, Soroka University Medical Center, Beer Sheva, Israel., Miskin Y; Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheva, Israel., Sagy I; Rheumatology Disease Unit, Soroka University Medical Center, Rager Bvd., Beer Sheva 84101, Israel.; Clinical Research Center, Soroka University Medical Center, Beer Sheva, Israel.; Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheva, Israel.
Jazyk:	angličtina
Zdroj:	Therapeutic advances in musculoskeletal disease [Ther Adv Musculoskelet Dis] 2024 Oct 07; Vol. 16, pp. 1759720X241274032. Date of Electronic Publication: 2024 Oct 07 (Print Publication: 2024).
DOI:	10.1177/1759720X241274032
Abstrakt:	Background: The incidence of various types of vasculitis conditions over time, specifically during coronavirus disease 2019 (COVID-19), is unknown. Objectives: We aimed to assess recent trends in vasculitides and the effect of the COVID-19 pandemic on these trends. Design: We conducted a retrospective analysis of Israel's largest Health Maintenance Organization, which covers over 4.7 million patients and represents 55% of the country. Methods: We calculated the age- and sex-adjusted incidence of giant cell arteritis (GCA), Takayasu, ANCA-associated vasculitis (AAV), IgA vasculitis, cryoglobulinemia, and Behcet's disease (BD) during 2007-2021. We analyzed associations of COVID-19 with the incidence of each of the examined conditions. Results: During 2007-2021, the adjusted annual incidence decreased from 7.9 (95% confidence interval (CI) 3.5-17.9) to 1.5 (95% CI 0.7-3.6) per 100,000 for GCA, from 5.2 (95% CI 2.7-11.1) to 1.5 (95% CI 0.7-3.3) per million for IgA vasculitis, and from 6.3 (95% CI 3.0-13.5) to 1.0 (0.5-2.5) per 100,000 for BD. The relative risks for these conditions decreased: 0.92 (95% CI 0.91-0.93), 0.93 (95% CI 0.89-0.98), and 0.90 (95% CI 0.85-0.94), respectively. The incidences of Takayasu, AAV, and cryoglobulinemia remained unchanged. The COVID-19 pandemic was not associated with changes in the incidence of any examined vasculitides. Conclusion: The incidences of GCA, IgA vasculitis, and BD decreased substantially in Israel during 15 years and were unaffected by the COVID-19 pandemic. Future studies should focus on possible environmental contributions to these findings. Competing Interests: The authors declare that there is no conflict of interest. (© The Author(s), 2024.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu